

Table 4. Subtype THZ diuretics analysis of risks of clinical outcomes between THZ cohort and comparison cohort.

	THZ cohort		Comparison cohort		SHR (95%CI)	P value
	No. cases	Per PY	No. cases	Per PY		
THZ-type						
Mortality	354	28.24	1140	26.79	1.05(0.93-1.14)	0.874
ESRD	493	38.76	1516	37.48	1.03(0.97-1.04)	0.837
CHF	507	34.23	1280	32.23	1.06(0.89-1.12)	0.761
AMI	426	31.65	1248	30.74	1.02(0.89-1.08)	0.653
PAOD	371	30.76	1188	28.60	1.07(0.92-1.12)	0.743
Stroke	549	32.76	1329	33.29	0.98(0.91-1.03)	0.887
Indapamide						
Mortality	437	17.24	1140	26.79	0.64(0.57-0.71)	<0.001
ESRD	665	25.19	1516	37.48	0.72(0.65-0.79)	<0.001
CHF	751	30.26	1280	32.23	1.01(0.92-1.10)	0.898
AMI	670	26.02	1248	30.74	0.89(0.81-0.98)	0.018
PAOD	495	18.50	1188	28.60	0.69(0.62-0.78)	<0.001
Stroke	750	29.77	1329	33.29	0.94(0.86-1.03)	0.177
Chlorthalidone						
Mortality	20	13.73	1140	26.79	0.62(0.40-0.97)	0.037
ESRD	23	16.22	1516	37.48	0.54(0.36-0.82)	0.004
CHF	32	23.37	1280	32.23	0.84(0.59-1.20)	0.335
AMI	31	22.56	1248	30.74	0.83(0.58-1.19)	0.314
PAOD	20	14.00	1188	28.60	0.60(0.39-0.94)	0.026
Stroke	37	27.35	1329	33.29	0.94(0.68-1.31)	0.728
Metolazone						
Mortality	78	27.91	1140	26.79	0.98(0.78-1.24)	0.862
ESRD	124	47.67	1516	37.48	1.28(1.06-1.54)	0.009
CHF	131	54.97	1280	32.23	1.60(1.33-1.92)	<0.001
AMI	111	43.32	1248	30.74	1.41(1.08-1.59)	0.007
PAOD	87	32.37	1188	28.60	1.06(0.85-1.32)	0.606
Stroke	106	41.67	1329	33.29	1.16(0.95-1.41)	0.147

Adjusted all comorbidities. AMI: acute myocardial infarction, CHF: congestive heart failure, ESRD: end stage renal disease, PAOD: peripheral arterial occlusive disease
 PY: patient year